Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATC1 and enhancing cell apoptosis

Rheumatology (United Kingdom)

Volumn 52, Issue 4, 2013, Pages 609-622

  Cheng, Chia Pi ^a   Sheu, Ming Jen ^b   Sytwu, Huey Kang ^c   Chang, Deh Ming ^d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c Graduate Institute of Life Sciences at TKU   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Decoy receptor 3; FASLG; NFATc1; Osteoclast

Indexed keywords

CASPASE 9; CYTOCHROME C; DECOY RECEPTOR 3; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR OF ACTIVATED T CELL CYTOPLASMIC CALCINEURIN DEPENDENT 1; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION;

ACID PHOSPHATASE; ADULT; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MICE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84875615620     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes343     Document Type: Article

References (51)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
2. Kotake S, Yago T, Kawamoto M, Nanke Y. Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial 'human osteoclastology'. J Bone Miner Metab 2012;30:125-35.
3. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203: 2673-82.
4. Redlich K, Hayer S, Ricci R et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27.
5. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30.
6. Pitti RM, Marsters SA, Lawrence DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703.
7. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses light-mediated apoptosis. J Biol Chem 1999;274:13733-6.
8. Migone TS, Zhang J, Luo X et al. TL1A is a TNF-like ligand for DR3 and TR6/DCR3 and functions as a T cell costimulator. Immunity 2002;16:479-92.
9. Zhang J, Salcedo TW, Wan X et al. Modulation of T-cell responses to alloantigens by TR6/DCR3. J Clin Invest 2001;107:1459-68.
10. Bai C, Connolly B, Metzker ML et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 2000;97: 1230-5.
11. Roth W, Isenmann S, Nakamura M et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001;61:2759-65.
12. Sung HH, Juang JH, Lin YC et al. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J Exp Med 2004;199:1143-51.
13. Ka SM, Sytwu HK, Chang DM, Hsieh SL, Tsai PY, Chen A. Decoy receptor 3 ameliorates an autoimmune crescenticglomerulonephritis model in mice. J Am Soc Nephrol 2007;18:2473-85.
14. Mueller AM, Pedre X, Killian S, David M, Steinbrecher A. The decoy receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol 2009;209:57-64.
15. Chen SJ, Wang YL, Kao JH et al. Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating th17 cells. Mol Immunol 2009;47: 567-74.
16. Chang YC, Hsu TL, Lin HH et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004;75:486-94.
17. Wu SF, Liu TM, Lin YC et al. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol 2004;75:293-306.
18. Bull MJ, Williams AS, Mecklenburgh Z et al. The death receptor 3-TNF-like protein 1a pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 2008; 205:2457-64.
19. Zhang J, Wang X, Fahmi H et al. Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol 2009;183: 5350-7.
20. Edwards JR, Sun SG, Locklin R et al. Light (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006;54:1451-62.
21. Hayashi S, Miura Y, Nishiyama T et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007;56:1067-75.
22. Cheng CP, Sytwu HK, Chang DM. Decoy receptor 3 attenuates collagen-induced arthritis by modulating T cell activation and B cell expansion. J Rheumatol 2011;38: 2522-35.
23. Ju JH, Cho ML, Moon YM et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 2008;181: 1507-18.
24. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19: 2499.
25. Evans KE, Fox SW. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 2007;8:4.
26. Asagiri M, Sato K, Usami T et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261-9.
27. Lee SE, Woo KM, Kim SY et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002;30:71-7.
28. Grigoriadis AE, Wang ZQ, Cecchini MG et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994;266:443-8.
29. Li X, Udagawa N, Itoh K et al. P38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002;143: 3105-13.
30. Miyazaki T, Katagiri H, Kanegae Y et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 2000;148:333-42.
31. Park H, Jung YK, Park OJ, Lee YJ, Choi JY, Choi Y. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 2005;175:7193-201.
32. Szymczyk KH, Freeman TA, Adams CS, Srinivas V, Steinbeck MJ. Active caspase-3 is required for osteoclast differentiation. J Cell Physiol 2006;209:836-44.
33. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 2004;11(Suppl. 1):S97-107.
34. Tang CH, Hsu TL, Lin WW et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem 2007;282:2346-54.
35. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of rank ligand. J Clin Invest 2000;106:1481-8.
36. Tai SK, Chang HC, Lan KL et al. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol 2012;188: 2464-71.
37. Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology 2003;144:5545-55.
38. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24.
39. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
40. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005;115:2625-32.
41. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 2006;372:92-102.
42. Matsumoto M, Kogawa M, Wada S et al. Essential role of p38 mitogen-activated protein kinase in cathepsin k gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004;279: 45969-79.
43. Oddie GW, Schenk G, Angel NZ et al. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone 2000;27:575-84.
44. Barrow AD, Raynal N, Andersen TL et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest 2011; 121:3505-16.
45. Trebec DP, Chandra D, Gramoun A, Li K, Heersche JN, Manolson MF. Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J Cell Biochem 2007;101:205-20.
46. Vignery A. Macrophage fusion: the making of osteoclasts and giant cells. J Exp Med 2005;202:337-40.
47. Miyamoto K, Ninomiya K, Sonoda KH et al. MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner. Biochem Biophys Res Commun 2009;383:373-7.
48. Kim WU, Kwok SK, Hong KH et al. Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther 2007;9:R42.
49. Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 1997;40: 1644-52.
50. Cheung TC, Coppieters K, Sanjo H et al. Polymorphic variants of light (TNF superfamily-14) alter receptor avidity and bioavailability. J Immunol 2010;185: 1949-58.
51. You RI, Chang YC, Chen PM et al. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008; 111:1480-8.